UPDATE 1-Gilead profit triples, hepatitis C drug sales total $2.3 bln

April 22 (Reuters) - Gilead Sciences Inc, which ignited a fierce debate over prescription drug prices, said its new $1,000 hepatitis C pill generated quarterly sales of $2.27 billion, helping the company's quarterly net profit nearly triple.